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PCLINICAL RESEARCH Coronary Artery Disease
Inverse Relationship of Blood Pressure Levels
to Sudden Cardiac Mortality and Benefit
of the Implantable Cardioverter-Defibrillator in
Patients With Ischemic Left Ventricular Dysfunction
Ilan Goldenberg, MD,* Arthur J. Moss, MD,* Scott McNitt, MS,* Wojciech Zareba, MD, PHD,*
W. Jackson Hall, PHD,† Mark L. Andrews, BBS,* for the MADIT-II Investigators
Rochester, New York
Objectives This study was designed to evaluate the relationship among blood pressure (BP) levels, risk of sudden cardiac
death (SCD), and benefit of the implantable cardioverter-defibrillator (ICD) in patients with ischemic left ventricu-
lar (LV) dysfunction.
Background Low BP has been shown to be associated with increased mortality in patients with LV dysfunction and heart fail-
ure. We hypothesized that increasing BP levels are associated with a reduction in the risk of SCD in this popula-
tion, thereby limiting ICD efficacy in a lower-risk subset.
Methods The independent contribution of systolic blood pressure (SBP) and diastolic blood pressure (DBP) to outcome was ana-
lyzed in 1,231 patients enrolled in the prospective MADIT-II (Multicenter Automatic Defibrillator Implantation Trial II).
Results Multivariate analysis showed that in the conventional therapy arm of the trial, 10-mm Hg increments in systolic
BP were independently associated with a respective 14% (p  0.01) and 16% (p  0.04) reduction in the risk of
cardiac mortality and SCD; similar trends were shown for DBP. Defibrillator therapy provided the least survival
benefit to patients in the lower-risk, upper SBP (130 mm Hg) and DBP (80 mm Hg) quartiles (hazard ratio
1.04 [p  0.89] and 1.05 [p  0.88], respectively), whereas a respective 39% and 38% (p  0.002) reduction in
the risk of death with ICD therapy was observed among patients with lower BP values.
Conclusions In patients with ischemic LV dysfunction, SBP and DBP levels show an inverse correlation with sudden cardiac
mortality. These noninvasive hemodynamic parameters may be useful for identifying lower-risk patients, in
whom the benefit of primary defibrillator implantation is more limited. (J Am Coll Cardiol 2007;49:1427–33)
© 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.11.042m
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Patients with a low ejection fraction (EF) and
heart failure have been shown to be at a high risk
for arrhythmic mortality and to obtain a survival
benefit with the implantable cardioverter-
defibrillator (ICD) (1–4). However, only about
one-third of the patients in whom an ICD is
mplanted for the primary prevention of sudden cardiac death
SCD) require device therapy for ventricular tachyarrhythmias
uring long-term follow-up (5). Thus, the benefit of the ICD
rom the *Cardiology Unit of the Department of Medicine and the †Department of
iostatistics and Computational Biology, University of Rochester Medical Center,
ochester, New York. The MADIT-II study was supported by a research grant from
uidant Corp., St. Paul, Minnesota, to the University of Rochester School of
edicine and Dentistry.f
Manuscript received September 21, 2006; revised manuscript received October 20,
006, accepted November 1, 2006.ay be more limited in a lower-risk subset of low EF
atients.
Previous studies that have evaluated patients with left
entricular (LV) dysfunction and heart failure have shown an
nverse correlation between blood pressure (BP) levels
See page 1434
nd the risk of all-cause mortality (6–13). However, the
elationship between BP levels and the risk of arrhythmic
ortality in this population has not been assessed. We hypoth-
sized that in patients with ischemic LV dysfunction enrolled
n the prospective MADIT-II (Multicenter Automatic Defi-
rillator Implantation Trial II) study, BP levels would show a
imilar inverse correlation with SCD risk, and that this
elationship may provide a useful risk stratification parameter
or primary ICD implantation.
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MADIT-II. The design and re-
sults of MADIT-II have been re-
ported elsewhere (4). Briefly,
1,232 patients with documented
previous myocardial infarction
(MI), EF 30%, and New York
Heart Association (NYHA) func-
tional class I to III were random-
ized to receive a prophylactic ICD
or conventional medical therapy in
a 3:2 ratio and were followed up
over a mean period of 20 months.
Screened patients were excluded
from enrollment if they had class
IV congestive heart failure, cor-
onary revascularization within
the previous 3 months, elapsed
interval from most recent MI of
1 month, or advanced medical
omorbidity. Baseline BP values were recorded during
nrollment, and were not available for 1 patient. The
emaining 1,231 patients were included in the present study,
f whom 742 patients were allocated to the ICD arm and
aseline Characteristics of Study Patients by SBP Quartiles
Table 1 Baseline Characteristics of Study Patients by SBP Qua
Characteristic <100 (n  288) 100–
SBP (mm Hg, mean  SD) 99 7 1
DBP (mm Hg, mean SD) 62 8
Age 65 yrs (%) 48
Female gender (%) 14
NYHA functional class 2 (%)† 69
Angina pectoris functional class 2 (%)† 30
BUN 25 mg/dl (%) 38
History of hypertension (%) 42
Diabetes mellitus (%) 30
Past CABG (%) 57
LBBB (%) 21
QRS duration 0.12 (%) 42
EF 25% 62
Atrial fibrillation (%) 9
Cigarette smoking anytime (%) 79
Heart rate 80 beats/min per ECG (%) 34
BMI 30 kg/m2 (%) 26
Medical therapy
ACE inhibitors (%) 77
ARBs (%) 11
Digitalis (%) 65
Beta-blockers (%) 62
Amiodarone (%) 6
Lipid-lowering agents (%)‡ 66
Diuretics (%) 79
p value for comparison of the distribution among the 4 SBP quartiles. †New York Heart Associatio
Statins comprised 95% of lipid-lowering agents.
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
DBP  diastolic blood
pressure
EF  ejection fraction
ICD  implantable
cardioverter-defibrillator
LV  left ventricular
MADIT-II  Multicenter
Automatic Defibrillator
Implantation Trial II
MI  myocardial infarction
NYHA  New York Heart
Association
SBP  systolic blood
pressure
SCD  sudden cardiac deathACE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker; BMI  body mass index;
ressure; ECG  electrocardiogram; EF  ejection fraction; ICD  implantable cardioverter-defibrillator;89 patients were allocated to the conventional therapy arm
f the trial.
efinitions and outcome. The BP indexes evaluated in
he current study included systolic blood pressure (SBP) and
iastolic blood pressure (DBP). Blood pressure values were
nalyzed by: 1) dividing BP indexes into approximate
uartiles (SBP: 100, 100 to 119, 120 to 130, and 130
m Hg; DBP: 60, 61 to 69, 70 to 79, and 80 mm Hg;
ith somewhat unequal numbers per quartile because of a
igh concentration of subjects at the decile values) and 2)
ncluding BP indexes as continuous measures in the multi-
ariate models. The effect of BP on the end points of
ll-cause mortality, cardiac death, and SCD was examined
n the conventional therapy arm, and the efficacy of ICD
herapy in reducing the risk of death was analyzed within
he prespecified BP quartiles. A modified Hinkle-Thaler
ystem was used to classify deaths as previously described
14).
tatistical analysis. Baseline characteristics by BP quartiles
ere compared and contrasted using the chi-square test.
aplan-Meier estimates, stratified by BP quartiles, for
ll-cause mortality in each treatment group were determined
nd statistically evaluated with the log-rank test. The Cox
roportional hazards regression model was used to evaluate
SBP (mm Hg)
p Value* 256) 120–130 (n  344) >130 (n  343)
3 124 4 145 12 NA
8 73 9 78 11 NA
54 62 0.001
16 16 0.82
64 63 0.11
30 26 0.61
27 27 0.01
54 69 0.001
38 37 0.09
58 59 0.76
15 17
33 35 0.16
45 39 0.001
7 9 0.76
83 78 0.41
26 28 0.21
28 32 0.39
78 79 0.56
12 13 0.57
54 56 0.03
62 62 0.99
7 10 0.08
67 67 0.66
72 73 0.17
A) and angina functional class represent the highest class during the 3 months before enrollment.rtiles
119 (n
13
69
48
16
59
28
31
45
34
55
21
38
50
9
82
27
30
74
14
60
63
5
63
76
n (NYHBUN  blood urea nitrogen; CABG  coronary artery bypass graft surgery; DBP  diastolic blood
LBBB  left bundle branch block; PP  pulse pressure; SBP  systolic blood pressure.
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April 3, 2007:1427–33 Blood Pressure and ICD Benefithe independent contribution of baseline clinical factors to
he development of end points. The baseline variables that
ad differences among the 4 SBP and DBP quartile groups,
sing a p value 0.10, were evaluated in the proportional
azards stepwise selection model. Covariates with a p value
0.05 in the proportional hazards model were included in
he final model. In an alternative analysis, gender, NYHA
unctional class, QRS duration 0.12 s, heart rate 80
eats/min, and medical therapy with beta-blockers and
ngiotensin-converting enzyme (ACE) inhibitors were
orced into the multivariate models as additional covariates.
he effect of BP on the end points of all-cause mortality,
ardiac death, and SCD in the conventional therapy arm,
nd ICD efficacy by BP subgroups was examined in a total
opulation model by including a treatment  BP interac-
ion term. All p values were 2-sided, and a value of p 0.05
as considered significant. Analyses were performed using
AS software (version 9.13, SAS Institute Inc., Cary, North
arolina).
esults
aseline BP indexes were normally distributed among study
atients and were similar in the ICD and conventional
herapy groups. The mean ( SD) SBP and DBP among
tudy patients was 122  18 mm Hg and 71  11 mm Hg,
espectively.
Baseline laboratory and clinical characteristics of study
atients by SBP quartile categories are shown in Table 1.
ultivariate Analysis: Predictors of Outcome in the Baseline Modend Effect of Blood Pressure Levels on Outcome in the Co vention
Table 2 Multivariate Analysis: Predictors of Outcome in the Baand Effect of Blood Pressure Levels on Outcome in the
All-Cause Mortality
HR (95% CI) p Value
Baseline model*
ICD vs. conventional 0.68 (0.51–0.89) 0.005
Age 65 yrs 1.82 (1.34–2.49) 0.001
EF 25% 1.55 (1.17–2.06) 0.003
BUN 25 mg/dl 2.21 (1.66–2.96) 0.001
SBP (mm Hg)†
Continuous analysis
Per 10–mm Hg increase 0.85 (0.76–0.95) 0.005
Quartile analysis
Q2 (100–119) vs. Q1 (100) 0.88 (0.51–1.52) 0.65
Q3 (110–119) vs. Q1 (100) 0.74 (0.44–1.25) 0.26
Q4 (120–130) vs. Q1 (100) 0.41 (0.22–0.77) 0.005
DBP (mm Hg)†
Continuous analysis
Per 10–mm Hg increase 0.79 (0.64–0.97) 0.02
Quartile analysis
Q2 (61–69) vs. Q1 (60) 0.71 (0.40–1.25) 0.23
Q3 (70–79) vs. Q1 (60) 0.60 (0.37–0.98) 0.04
Q4 (80) vs. Q1 (60) 0.41 (0.21–0.78) 0.007
The baseline model includes variables that had differences between the 4 SBP and DBP quartile g
nd had a p value 0.05. †Models were analyzed in the total population and adjusted for age 6
he main effects of age, BUN, and EF in the SBP and DBPmodels were virtually identical to those pre
lass, QRS duration0.12 s, heart rate80 beats/min, and medical therapy with beta-blockers a
nd points.
CI  confidence interval; HR  hazard ratio; SCD  sudden cardiac death; other abbreviations as in Tahe mean DBP correlated with SBP quartiles. The propor-
ion of patients with an older age, a history of hypertension,
nd diabetes mellitus increased with increasing SBP quar-
iles, whereas the proportion of patients with a lower EF
nd higher baseline blood urea creatinine levels was in-
ersely correlated with SBP. Medical therapies with ACE
nhibitors, beta-blockers, and lipid-lowering agents were
dministered to a similar proportion of patients among SBP
uartiles, whereas therapy with digitalis was administered to
higher proportion of patients with low SBP. Baseline
linical characteristics and medical therapies were similarly
istributed among DBP quartiles (not shown).
lood pressure indexes and mortality in the conventional
herapy group. Baseline variables that showed differences
mong the 4 SBP and DBP quartiles and were significantly
ssociated with each outcome measure included age 65
ears, EF 25%, and blood urea nitrogen 25 mg/dl
Table 2). The effect of SBP and DBP on outcome in the
onventional therapy group, after adjustment for these
aselines covariates, is presented in Table 2.
The risk of cardiac and SCD declined by 14% and 16%,
espectively, for every 10-mm Hg increment in SBP, and by
8% and 20%, respectively, for every 10-mm Hg increment
n DBP. Quartile analysis showed a significant reduction in
he risk of all-cause mortality and cardiac death with
ncreasing BP quartiles, whereas the decline in the risk of
CD was apparent mainly among patients with upper-
uartile SBP (59% reduction) and DBP (67% reduction)
erapy Group
e Model
ventional Therapy Group
Cardiac Death SCD
HR (95% CI) p Value HR (95% CI) p Value
0.62 (0.46–0.85) 0.003 0.36 (0.22–0.57) 0.001
1.64 (1.17–2.32) 0.005 2.08 (1.24–3.47) 0.005
1.58 (1.15–2.17) 0.005 1.98 (1.24–3.17) 0.004
2.49 (1.80–3.45) 0.001 1.99 (1.25–3.18) 0.004
0.86 (0.76–0.97) 0.01 0.84 (0.71–0.99) 0.04
0.88 (0.48–1.62) 0.69 1.02 (0.46–2.25) 0.96
0.76 (0.43–1.34) 0.34 0.99 (0.48–2.04) 0.98
0.47 (0.24–0.92) 0.02 0.41 (0.17–0.97) 0.04
0.82 (0.65–1.02) 0.07 0.80 (0.60–1.05) 0.09
0.76 (0.41–1.43) 0.40 0.51 (0.22–1.17) 0.11
0.68 (0.40–1.17) 0.17 0.58 (0.30–1.12) 0.10
0.40 (0.19–0.84) 0.01 0.33 (0.13–0.84) 0.02
sing a p value0.10, which were evaluated in the proportional hazards stepwise selection model
UN 25 mg/dl, EF 25%, treatment group, BP category, and treatment group  BP interaction;
for the baseline model; findings were similar after further adjustment for gender, NYHA functional
otensin-converting enzyme inhibitors; no significant treatment BP interaction was shown for alllal Th
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Blood Pressure and ICD Benefit April 3, 2007:1427–33alues (Table 2). Consistently, the relationship between
BP and DBP and mortality (Figs. 1A and 1B) showed a
inear reduction in the rates of all-cause and cardiac mor-
ality with increasing SBP (2-fold decrease) and DBP
uartiles (3-fold decrease), whereas the decline in the rate
f SCD with increasing SBP and DBP quartiles was
onlinear, and was prominent mainly among patients in the
pper BP quartiles.
elationship of BP indexes to ICD benefit. In multivar-
ate analysis, defibrillator therapy was associated with an
verall significant 32% reduction in the risk of death in the
otal study population (Table 2). When ICD efficacy was
nalyzed within BP subgroups (Table 3), no survival benefit
as shown among patients with SBP 130 mm Hg and
BP 80 mm Hg (hazard ratio [HR] 1.04 [p  0.89] and
.05 [p  0.88], respectively), whereas among patients with
BP 130 mm Hg and DBP 80 mm Hg, defibrillator
herapy was associated with a respective 39% (p  0.002)
nd 38% (p  0.002) reduction in mortality risk. The
enefit of the ICD was consistent within the individual
ower 3 SBP and DBP quartiles (Table 3), whereas no ICD
enefit was consistently shown when narrower ranges
Figure 1 Mortality Rates by Systolic
and Diastolic Blood Pressure
All-cause (solid diamonds, solid lines), cardiac (solid squares, dashed lines)
and sudden cardiac (solid circles, dotted lines) mortality rates per 100
person-years by (A) systolic blood pressure quartiles and (B) diastolic blood
pressure quartiles.ithin the SBP130 mm Hg quartile (131 to 140 mm Hg:
vR 1.05 [p  0.87]; 140 mm Hg: HR 1.02 [p  0.69])
nd the DBP 80 mm Hg quartile (80 to 85 mm Hg: HR
.18 [p  0.64]; 85 mm Hg: HR 0.97 [p  0.94]) were
nalyzed. Accordingly, Kaplan-Meier survival curves in the
treatment groups among patients with SBP130 mm Hg
nd DBP 80 mm Hg (Figs. 2A and 3A, respectively)
howed a significantly lower 2-year mortality rate in the
CD group (17%) compared with the conventional therapy
roup (25%), whereas the 2-year probability of death was
imilar in the ICD and conventional therapy groups among
atients with SBP 130 mm Hg (13% and 12%, respec-
ively) (Fig. 2B) and DBP 80 mm Hg (11% and 12%,
espectively) (Fig. 3B).
In a further exploratory analysis, ICD efficacy among
atients in whom both SBP and DBP levels were elevated at
he upper quartile (n  172) was compared with the benefit
f device therapy among all other study patients (in whom
ither SBP or DBP levels [or both] were below the
espective upper quartile value [n  1,059]). In the former
ubgroup of lower-risk patients, no ICD benefit was ob-
erved (HR 2.43 [95% confidence interval 0.70 to 8.48];
 0.16), whereas in the latter subgroup defibrillator
herapy was associated with a significant survival benefit
HR 0.62 [95% confidence interval 0.46 to 0.82]; p 
.001). Notably, a significant ICD  BP interaction was
hown for the comparison of ICD benefit between the 2
ubgroups (p  0.03), suggesting a significant reduction in
CD efficacy among patients who maintained elevated levels
f both SBP and DBP.
iscussion
he main finding of this study is that patients with ischemic
V dysfunction who maintain elevated SBP and DBP have
urvival Benefit of ICD by SBP and DBP Quartiles*
Table 3 Survival Benefit of ICD by SBP and DBP Quartiles*
HR 95% CI p Value
SBP (mm Hg)
Q4: 130† (n  343) 1.04 0.55–1.97 0.89
Q1–3: 130† (n  888) 0.61 0.45–0.83 0.002
Q1: 100 (n  288) 0.65 0.40–1.07 0.09
Q2: 100–119 (n  256) 0.56 0.31–1.00 0.05
Q3: 120–130 (n  344) 0.62 0.36–1.06 0.08
DBP (mm Hg)
Q4: 80‡ (n  328) 1.05 0.54–2.05 0.88
Q1–3: 80‡ (n  903) 0.62 0.46–0.84 0.002
Q1: 60 (n  286) 0.57 0.35–0.93 0.02
Q2: 61–69 (n  210) 0.60 0.31–1.11 0.10
Q3: 70–79 (n  407) 0.65 0.40–1.07 0.09
HR indicates the ICD versus conventional risk of death within each blood pressure quartile;
ndings were adjusted for age65 yrs, BUN25 mg/dl, EF25%, treatment group, BP category,
nd treatment group  BP category interaction; the main effects of age, BUN, and EF in each BP
odel were nearly identical to those presented in Table 2; findings were similar after further
djustment for gender, NYHA functional class, QRS duration 0.12 s, heart rate 80 beats/min,
nd medical therapy with beta-blockers and ACE inhibitors; no significant interaction between
edical therapy with either beta-blockers or ACE inhibitors and ICD benefit was observed
ithin analyzed BP categories. †p value for treatment  SBP category interaction  0.13. ‡p
alue for treatment  DBP category interaction  0.11.
Abbreviations as in Tables 1 and 2.
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April 3, 2007:1427–33 Blood Pressure and ICD Benefitlower risk of SCD, and that these noninvasive hemody-
amic indexes may be useful for identifying higher-risk and
ower-risk subgroups within the low EF population when
rimary ICD implantation is considered.
Abundant data from major trials have consistently shown
he detrimental cardiovascular effects of hypertension and the
stablished benefit of treating hypertension in reducing the risk
f heart failure and cardiovascular mortality (15–17). These
tudies, however, have focused on younger hypertensive
atients, mostly with preserved cardiac function. Our find-
ng that high, not low, BP is predictive of favorable survival
n patients with reduced LV function (30%) and a
ompensated heart failure functional class is consistent with
revious published data in this population (6–13). How-
ver, in the current study we extended these observations,
nd have shown that increased systolic and diastolic pres-
ures are also associated with a reduction in the risk of
udden cardiac mortality.
Low EF had been identified as a risk factor for subse-
Figure 2 ICD Benefit by SBP
Kaplan-Meier estimates of probability of all-cause mortality by treatment
group among patients with (A) systolic blood pressure (SBP) quartiles
1 to 3 and (B) SBP quartile 4. ICD  implantable cardioverter-defibrillator.uent cardiac mortality and SCD (18), and has become theajor criterion for primary prevention with ICD therapy
19). However, data from MADIT-II have shown that only
pproximately one-third of patients received appropriate
CD therapy for ventricular tachycardia or fibrillation
hroughout the course of the trial (5). Therefore, it is
mportant to identify low-risk patients within the low EF
roup. To date, suggested risk factors, including QRS
uration or advanced NYHA functional class, were not
hown to stratify patients with LV dysfunction into high-
isk and low-risk groups (4). Furthermore, inducibility with
lectrophysiological testing was not shown to be clinically
seful in identifying patients who should receive primary
CD implantation for the prevention of SCD (20). In the
urrent study we have shown that noninvasive BP indexes
dentify patients with a lower risk of SCD, and therefore
ay be useful in risk stratification for primary ICD therapy
n patients with advanced LV dysfunction. The decline in
he rate of SCD with increasing BP values was nonlinear,
nd was prominent mainly among patients in the upper SBP
nd DBP quartiles. Accordingly, these lower-risk subgroups
Figure 3 ICD Benefit by DBP
Kaplan-Meier estimates of probability of all-cause mortality by treatment
group among patients with (A) diastolic blood pressure (DBP) quartiles
1 to 3 and (B) DBP quartile 4. ICD  implantable cardioverter-defibrillator.
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Blood Pressure and ICD Benefit April 3, 2007:1427–33eceived the least benefit from primary ICD implantation.
oreover, a significant interaction effect was shown be-
ween ICD therapy and the BP category comprising pa-
ients who maintained elevated levels of both SBP and
BP, suggesting that the benefit of the ICD is significantly
ttenuated in this subset of patients.
Notably, the relationship between ICD efficacy and BP
ersisted after multivariate adjustment for EF, NYHA
unctional class, heart rate, or concurrent therapies with
P-lowering medications. Therefore, our findings regard-
ng the effect of BP on outcome seem to be independent of
ther markers of health in this population. The ability to
aintain elevated systolic and diastolic pressures despite a
ow EF may indicate better myocardial reserve, which
ossibly may be associated with improved survival and
educed risk of cardiac and SCD. It is also possible that in
atients with LV dysfunction who have lower BP levels,
here is maladaptive activation of catecholamine and other
eurohormonal counter-regulatory systems that potentially
ontribute to increased risk for arrhythmias and death.
tudy limitations. Several limitations of this study should
e noted. No conclusions on the benefit of antihypertensive
reatment or current medical therapy recommendation for
atients with heart failure can be drawn on the basis of this
tudy. Beta-blockers and ACE inhibitors have been shown
o prolong life in this high-risk population, and should be
dministered to every patient with advanced LV dysfunction
ithout contraindications.
The power of this subanalysis of MADIT-II to detect a
tatistically significant ICD survival benefit within individ-
al BP quartiles was limited because of a relatively small
ample size. However, within each of the lower 3 SBP and
BP quartiles we observed similar trends for ICD efficacy,
hereas among the upper SBP and DBP quartiles no ICD
enefit was shown after multivariate adjustment. Further-
ore, despite a relatively small sample size, we observed a
arginally significant treatment  BP interaction when the
pper SBP and DBP quartiles were compared with the
espective lower 3 BP quartiles, and a statistically significant
eduction in ICD efficacy among patients who maintained
levated levels of both SBP and DBP.
Beta-blockers were administered to approximately two-
hirds of study patients. Therefore, the current results may
ot represent the effect of BP on outcome in patients who
re receiving full medical therapy for heart failure. However,
ur findings regarding ICD efficacy within the BP sub-
roups persisted after multivariate adjustment for medical
herapies, and no interaction was shown between the effects
f beta-blockers or ACE inhibitors on outcome and ICD
fficacy, suggesting that the findings regarding the relation-
hip among BP, risk of SCD, and ICD benefit are inde-
endent of adjunctive medical therapies.
The present study results are only applicable to the
ADIT-II study population, which is composed of pa-
ients with coronary heart disease and LV dysfunction.
herefore, data on the relationship between BP and ICDenefit in patients with nonischemic cardiomyopathy can-
ot be derived from the current analysis. In addition,
ollow-up data on BP levels were not consistently collected
n MADIT-II, precluding a comprehensive analysis of the
ffect of time-dependent changes in BP on outcome.
onclusions
e have shown that patients with ischemic LV dysfunction
ho maintain elevated SBP and DBP have a lower risk of
CD, and may therefore derive less benefit from primary
CD implantation. Validation of these findings in subanaly-
es of major randomized ICD trials and the ongoing
ADIT-II ICD Registry would provide important prog-
ostic data in this high-risk population. At present, our
ndings suggest that follow-up of BP levels should be an
mportant component of risk assessment in patients consid-
red for primary ICD implantation.
eprint requests and correspondence: Dr. Ilan Goldenberg,
eart Research Follow-Up Program, Box 653, University of
ochester Medical Center, Rochester, New York 14642. E-mail:
lan.Goldenberg@heart.rochester.edu.
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